Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the ...

SKY-0515 is Skyhawk's investigational small molecule RNA splicing modifier developed through the company's novel RNA-splicing ...

The FDA provided a Prescription Drug User Fee Act (PDUFA) action date of November 18, 2025, and indicated it is not currently planning to hold an advisory committee meeting. In February ...

A chemical found in the atmosphere around an exoplanet that leads researchers to believe the planet may harbor life is called ...

Discovered in the state of Ceará, Brazil, the novel coronavirus shares similarities with the virus responsible for Middle ...

Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of ...

An Eddie Woods-consigned colt by Gun Runner sold for an Ocala Breeders' Sales record when he dropped the hammer for $3 ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) has received a consensus recommendation of “Buy” from the ...

Consignor Eddie Woods stood in the back ring March 13, trying his best to articulate the thoughts whipping through his mind ...

Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at Needham & Company LLC in a research report issued on Thursday,Benzinga reports.

Ipsen has expanded its R&D pipeline once again, agreeing a $1.8 billion alliance with Skyhawk Therapeutics focused on the development of RNA-targeting therapies for rare neurological diseases.

Now the nation’s top health official, Kennedy is reevaluating the US Health and Human Services’s contract with Moderna, which ...